K
Kither Biotech
Development of new products for targeted therapies, in particular to fight airway disease and targeting PI3Ks with safety | Academic spin-off of the University of Turin
About Kither Biotech
Kither Biotech is a biopharmaceutical company spun-off from the University of Turin, focused on the development of treatments for rare pulmonary diseases. The company's lead product candidate, KIT2014, is an inhaled peptide therapy designed to address cystic fibrosis by enhancing CFTR protein function, inducing bronchodilation, and reducing inflammation.
Read full description
Kither Biotech's business model centers on the research and development of proprietary drug candidates to address unmet medical needs in the respiratory field. The company's primary clients are patients suffering from rare pulmonary conditions, with a focus on cystic fibrosis and idiopathic pulmonary fibrosis. Kither Biotech operates in the pharmaceutical and biotechnology market, a sector characterized by long development cycles, stringent regulatory requirements, and high potential returns. The company generates value through the advancement of its drug pipeline, with the ultimate goal of out-licensing or co-developing its assets with larger pharmaceutical partners.
At a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Turin, Italy
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 73.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Respiratory, Spinout, Disease, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Kither Biotech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2022 | $20M | $81M | CDP Venture Capital · 3B Future Health Fund · Venture Ace · Italian Angels for Growth | ↗ |
| SERIES A✓Equity / VC | Jul 2019 | $6.2M | $25M | Italian Angels for Growth · CDP Venture Capital · ACE Incubator · Elysia | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Kither Biotech is 540 monthly website visits, down 46% over the last three months. Kither Biotech's team declined 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Italian Angels for Growth
CDP Venture Capital
ACE Incubator
Elysia
Claris Ventures- 2I2invest
3B Future Health Fund- VAVenture Ace
- 2I2 Invest
- A6Alef 6
Investors' club
Ersel Asset Management
Other known investors6 additional known investors
Despina
University of Turin
2i3T
Elysia Capital
Enne3- FRFederico Raccah
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kither Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kither Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.